A recent study reported that long‑acting injectable formulations of buprenorphine significantly lowered the need for inpatient care among patients with opioid use disorder. Researchers documented reduced hospital stays and readmissions after implementing extended‑release buprenorphine in treatment pathways. Investigators emphasized operational benefits—improved continuity of care and lower acute care burden—while noting implementation barriers such as upfront drug cost and supply chain considerations. The study suggests long‑acting injectable buprenorphine can shift services from hospitals to outpatient settings. For payers and providers: the data support broader adoption of depot formulations as a strategy to reduce acute care utilization and may influence formulary decisions and addiction treatment models.